Appointment of Interim CEO

AI SummaryClose X

SkinBioTherapeutics plc has appointed Rachel Parsonage as Interim CEO for a six-month period, effective immediately, to help stabilize the business and oversee a thorough investigation into current issues. Parsonage brings over 32 years of experience in the consumer and wellness sector, with a proven track record in stabilizing companies, managing stakeholders, and driving sales and IP commercialization. This appointment is part of the company's plan to resolve issues quickly and return to growth, with a focus on balancing investigation thoroughness with a cost-benefit framework to reduce uncertainty.

Disclaimer*

UK 100

Latest directors dealings